ng101m
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2020 (NCT04303195)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06500429 | Phase 2 | Jun 24, 2024 | Neurogastrx, Inc. |
| NCT05984927 | Phase 1/Phase 2 (Phase 2) | Sep 8, 2023 | Neuracle Genetics, ORA, Inc. |
| NCT04373785 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2020 | NeuGATE Theranostics |
| NCT04303195 | Phase 2 | Mar 31, 2020 | Neurogastrx, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurogastrx, Inc. | For profit | 2 | 2 | 1 | 2020 |
| NeuGATE Theranostics | For profit | 1 | 1 | 1 | 2020 |
| Neuracle Genetics | For profit | 1 | 1 | 1 | 2023 |
| ORA, Inc. | For profit | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1